Johnson and Johnson exit the bid to acquire Pfizer’s consumer unit

By Catherine Sturman
Global pharmaceutical giant Johnson and Johnson have exited its bid to acquire Pfizer’s consumer unit, which it previously acquired back in 2006. The...

Global pharmaceutical giant Johnson and Johnson have exited its bid to acquire Pfizer’s consumer unit, which it previously acquired back in 2006. The decision has come as a surprise, yet competitors GlaxoSmithKline (GSK) and Reckitt Benckiser remain in the running.

Bidders have until the 1 February to submit an offer, yet bidders will have to dig deep in their pockets. It has been reported that the business is wanting bids no less than $20 billion.

Nonetheless, competition is to acquire the unit is not only of the interest of pharmaceutical giants. With a faithful customer base surrounding its over-the-counter drugs, such as Advil and Centrum, many industries are exploring the potential of investing in healthcare and what it could bring in terms of future growth.

See also

It has been reported that Swiss confectionary company Nestle is looking at bidding for the division, which would support the company’s growing healthcare focus. It has recently sold its US confectionary business to Ferrero for $2.8 billion, further highlighting the company’s change in strategy.

However, for pharmaceutical companies, the acquisition could make the successful bidder a significant player in the consumer health market, an area which is growing year on year amidst an increasing tech-savvy market.

 

Share

Featured Articles

Honeywell comments on post-pandemic air quality challenges

Honeywell’s Sarah James calls for air sensors to ensure good air quality & Stefano D’Agostino explores how technology can help improve indoor air quality

Oracle's generative AI prioritises patient healthcare

Oracle's vision for better healthcare focuses on improving medical professionals quality time with patients, with Oracle Clinical Digital Assistant

2San's new app provides vital diagnostic product insights

2San’s leap forward in self diagnostics will bring ‘Better Care, Better Life’ to all, in a new step for 2San’s post-COVID-19 healthcare technology

Cylera’s Richard Staynings on healthcare cybersecurity

Technology & AI

Amazon Prime & One Medical to revolutionise healthcare

Digital Healthcare

Creating robust pharma supply chains with delivery devices

Medical Devices & Pharma